Study to Examine Safety, Tolerability and Effect on Body Weight of Subcutaneous AC2307 in Obese or Overweight Subjects
Study identifier:CFA104
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
Study Complete
Official Title
A Phase 2, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging study to examine the safety, tolerability, and effect on body weight of subcutaneous AC2307 in obese or overweight subjects
Medical condition
obesity
Phase
Phase 2
Healthy volunteers
No
Study drug
AC2307, placebo
Sex
All
Actual Enrollment
273
Study type
Interventional
Age
18 Years - 65 Years
Date
Study Start Date: 01 Dec 2008
Primary Completion Date: 01 Sept 2009
Study Completion Date: 01 Sept 2009
Study design
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind
Primary Purpose: Treatment
Verification:
Verified 01 Dec 2014 by AstraZeneca
Sponsors
AstraZeneca
Collaborators
-
Inclusion and exclusion criteria
Loading...
No locations available
| Arms | Assigned Interventions |
|---|---|
| Experimental: 1 | Drug: AC2307 subcutaneous, twice daily, low dose |
| Experimental: 2 | Drug: AC2307 subcutaneous, twice daily, middle dose |
| Experimental: 3 | Drug: AC2307 subcutaneous, twice daily, high dose |
| Placebo Comparator: 4 | Drug: placebo subcutaneous, twice daily, low dose |
| Placebo Comparator: 5 | Drug: placebo subcutaneous, twice daily, middle dose |
| Placebo Comparator: 6 | Drug: placebo subcutaneous, twice daily, high dose |
Contacts
Investigators
Principal Investigator
Hubert Chen
Amylin Pharmaceuticals
